Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: Newly Established Corporate Venture Initiative Strategically Invests in Life Sciences and AI-Powered Healthcare Technologies

3 Feb

The firm is a newly established corporate venture capital operating platform launched as part of a large global conglomerate’s corporate strategy focused on value creation and long-term growth. The firm represents the parent organization’s first company-wide corporate venture capital initiative and is designed to make flexible investments across a broad range of sectors, particularly those with large future markets and high growth potential where the parent organization can contribute differentiated value through global networks, industry and customer access, and technology and academic partnerships.  

Through the firm, the parent organization aims to accelerate collaboration with startups, identify business opportunities beyond existing core businesses, commercialize emerging technologies, support industrial application, and enable international expansion.  

The firm primarily focuses on early-stage companies, starting at Seed stage, but is able to invest across Seed through later-stage opportunities. The firm invests across a broad set of innovation-driven sectors, including AI, software, bio and healthcare, robotics, aerospace, next-generation computing, and other advanced technology domains. The investment strategy emphasizes areas where the firm can actively support commercialization, industrial deployment, and global scaling by leveraging the parent organization’s extensive industrial ecosystem.  

From a company and management team perspective, the firm partners with startups that are aligned with a broader transformation agenda and are capable of leveraging a global industrial platform to achieve scalable growth and international reach. The firm favors founding teams with deep technical expertise, strong commercialization potential, and the ability to engage effectively with industry, academic, and corporate networks. Investments are typically structured as equity participation, with active strategic support through customer access, supply-chain capabilities, and global operational resources to accelerate growth and value creation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , ,

Hot Investor Mandate: Multi-Billion AUM VC Firm Invests Up to $20M in Innovative Biotech and Medtech Platforms and Products

27 Jan

A venture capital platform specialized in life sciences and medical technology manages multiple funds with total assets under management of approximately $1.5B. The firm has been operating since 2014 and is managed by a professional team with diverse and deep industry experience. To date, the firm has completed more than 90 investments in high-growth-potential companies. Typical allocation sizes for their RMB funds range from RMB 30M to RMB 150M, with the ability to invest up to RMB 200M. For the USD fund, typical investments range from $5-10M, with the ability to invest up to $20M. 

The firm is open to investing globally across the broader biomedical sector, including medtech and biotech or therapeutics. The firm focuses on technology-driven, innovative platforms and products that demonstrate clear differentiation and meaningful value creation for patients and the healthcare system overall. Within biotech and therapeutics, the firm prefers companies at the angel or venture stages, particularly those addressing significant unmet clinical needs. 

From a company perspective, the firm prefers opportunities that are technology-driven, commercially viable, and capable of solving real-world healthcare problems. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Corporate VC Arm of Global Pharma Strategically Invests in Pre-Clinical Therapeutics in Areas Including Oncology, CNS, Immunology

27 Jan

A corporate venture capital arm of a global pharmaceutical company with a long operating history and an international footprint is actively seeking new investments. The parent organization operates worldwide and has expanded its global reach through strategic acquisitions in recent years. As part of its broader open innovation strategy, the parent organization actively pursues in- and out-licensing, early-stage partnerships, and strategic investments. The firm is responsible for executing strategic investments that support future partnering opportunities and help build the parent organization’s therapeutic pipeline. 

The firm was established a few years ago and operates from the United States. The firm manages an evergreen fund and focuses on pre-clinical startups with differentiated platforms and first-in-class programs in human therapeutics. The firm participates in Seed and Series A financing rounds, typically investing up to USD $5M initially, with the ability to invest up to USD $10M per company through follow-on capital. The firm is open to engaging with companies globally and has built a portfolio of more than a dozen investments, primarily across Europe and the United States. 

The firm targets pre-clinical to pre-IND, in-human therapeutics companies. Key areas of interest include oncology, neurology, immunology, and specialty disease areas such as fibrosis, endocrine disorders, and rare genetic diseases. The firm is modality-agnostic and considers small molecules, antibodies, nucleic acid-based therapies, and gene therapies. The firm does not invest in medical devices or diagnostics. 

The firm does not lead financing rounds. When co-investing or participating in syndicated rounds, the firm requires a board observer seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

Hot Investor Mandate: VC Firm With Multiple Life Science-Focused Funds Seeks Early-Stage Therapeutics and AI-Enabled Technologies 

27 Jan

A venture capital platform associated with a leading global life sciences services provider manages multiple funds and focuses on investing in early-stage life science companies. The firm’s investment sweet spot spans from Seed through Series B stages. Initial check sizes typically range from USD $2–10M, with the ability to provide follow-on capital. The firm is open to both leading and co-investing and considers board or observer seats on a case-by-case basis. Backed by a major contract research organization, the firm leverages deep expertise in biotech research and development to deliver value beyond capital. 

The firm invests in biotech therapeutics, including small molecules, biologics, and drug discovery programs. Key areas of interest include oncology, immunology and inflammation, central nervous system diseases, and metabolic diseases, covering a broad range of commonly pursued indications. The firm evaluates opportunities from the pre-IND stage through Phase I clinical trials. In addition, the firm focuses on innovative AI-enabled healthcare opportunities with strong technological differentiation, including AI-integrated medical devices such as surgical robotics, brain–computer interfaces, and smart imaging systems, as well as AI-driven diagnostics, drug discovery acceleration platforms, and intelligent healthcare solutions designed to improve clinical efficiency and data-driven decision-making. 

The firm does not impose specific requirements regarding the composition of a company’s management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Early-Stage Focused Venture Fund Looks for Neuropsychiatric Opportunities from Pre-Seed to Series A Rounds

27 Jan

A venture capital firm focused on early-stage neuropsychiatric opportunities invests from Pre-Seed to Series A stages, with initial check sizes typically ranging from USD $50K to $1M. The firm is open to acting as the first institutional investor and may provide follow-on capital. The firm is open to both leading and co-investing and will consider board or observer seats on a case-by-case basis. The firm participates in both traditional equity rounds and SAFE agreements. While the firm primarily focuses on U.S.-based companies, the firm is also open to global opportunities. 

The firm invests in neuropsychiatric treatments and technologies aimed at improving mental health and general wellness. Areas of interest include psychedelic medicine, brain–computer interfaces, therapeutic platforms, precision diagnostics, and related technologies. For biotech opportunities, the firm prefers assets that are at or near the IND stage. For medtech opportunities, the firm is willing to engage earlier in the development process. 

The firm does not have strict requirements regarding management team composition but strongly prefers to work with founders who have prior pharmaceutical or biotech industry experience or a demonstrated track record of successful entrepreneurship. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: VC Firm With US and Asia Offices Invests in Early-Stage Life Science Companies in Seed to Series A Rounds

16 Dec

A venture capital firm with offices in US and Asia primarily invests in Seed and Series A rounds, although the firm is not stage-focused or valuation sensitive, as the core focus is on return opportunities. The firm has a global investment team covering healthcare, consumer, enterprise, frontier, fintech, and more. The firm invests globally and typically acts as a co-investor, making approximately 2–5 new portfolio investments per quarter and 2–5 follow-on investments per quarter. Initial check sizes can be up to $1M USD. 

As a generalist investor within healthcare, the firm seeks transformative technologies that shape the future of the sector. 

The firm values founders with a clear vision to solve fundamental problems at the root cause level, emphasizing cost-effective solutions that can benefit large populations. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Global Pharma With Investment Subsidiary Seeks Companies Developing Novel Drugs, Open to Various Modalities

16 Dec

The firm is a publicly listed pharmaceutical company with a global workforce and an international footprint that includes over 40 branches and subsidiaries worldwide. The firm’s core businesses are active pharmaceutical ingredients and generic drugs, while the firm is rapidly expanding into innovative drug development, including small molecules, biologics, and cell and gene therapies. A U.S.-based subsidiary operates as an integrated platform with research and development, manufacturing, and commercial capabilities, supplying generic drugs to major pharmacy chains, mass retailers, and grocery channels. 

Another subsidiary of the firm is responsible for equity investments and business development activities, including in-licensing and supplier or distributor partnerships, across both the China and U.S. markets. 

The firm is most interested in companies developing novel drugs across biologics, cell therapy, gene therapy, repurposed drugs, and biosimilars. From a development-stage perspective, the firm prefers programs at or before the NDA stage, including preclinical, Phase I, Phase II, Phase III, and NDA-ready assets. 

In addition to general equity investment and business development opportunities, the firm has particular interest in late-stage clinical assets that can be in-licensed and introduced into the China market, technologies that improve API manufacturing and production efficiency, and injectable drug products. The firm is also interested in distribution rights in China for both innovative and generic drugs, as well as distribution rights in the United States, primarily for generic drugs. 

From a company and management team perspective, the firm generally favors partners with strong scientific and technical capabilities, clear development and regulatory strategies, and high-quality data packages that support clinical and commercial potential. The firm typically values management teams that demonstrate execution capability, openness to strategic collaboration, and a willingness to engage in cross-border partnerships aligned with manufacturing, regulatory, and commercialization objectives. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

← Older Entries
Newer Entries →